Home / Investors / Overview

Company Information

CymaBay Therapeutics (Nasdaq: CBAY)

We are a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need. We are evaluating seladelpar in primary biliary cholangitis (PBC). We also have a product program in earlier development that features a unique mechanism of action with potential in chronic diseases.

Stock Information

Last Change Volume

Shares Outstanding: 10,064,495
(as of March 3, 2014)

Company Information

CymaBay Therapeutics
7575 Gateway Blvd
Suite 110
Newark, CA 94560

Investor Relations

LifeSci Advisors, LLC
Hans Vitzthum
(617) 430-7578

Recent News


CymaBay Reports Third Quarter and Nine Months Ended September 30, 2022 Financial Results and Provides Corporate Update


CymaBay Therapeutics to Report Third Quarter of 2022 Financial Results on Monday, November 14, 2022


CymaBay Therapeutics Presents Additional Analyses from Clinical Studies of Seladelpar for Patients with Primary Biliary Cholangitis at The Liver MeetingĀ® 2022

Q3 2022 Quarterly Results